急性胰腺炎(AP)是一种常见的消化系统疾病,即胆道疾病、大量酒精、暴饮暴食等引起的胰酶激活继以胰腺局部炎症反应为主要特征伴或不伴有其他器官功能改变的疾病。其中20%~25%的病人会进展为重症急性胰腺炎(SAP),病死率高达30%~50%,造成巨大的社会医疗负担。研究表明SAP患者存在不同程度的血液高凝状态或血栓形成,进一步发展为凝血功能障碍。在SAP的治疗中,早期合理应用抗凝药物可明显改善胰腺微循环障碍和炎症反应,同时有利于改善其他重要脏器的灌注,阻止病情恶化,可减少SAP的病死率。因此,抗凝治疗是遏制SAP凝血功能障碍的必要治疗手段。作者对SAP凝血功能障碍机制及抗凝治疗的相关研究进行综述。

[1] YADAV D,LOWENFELS A B.The epidemiology of pancreatitis and pancreatic cancer[J].Gastroenterology,2013,144(6):1252-1261.
[2] ELISABETTA M.Pharmacological interventions for acute pancreatitis[J].Cochrane Database Syst Rev,2017,4(10):1384.
[3] 朱清芳.奥曲肽微量泵持续注射治疗急性胰腺炎效果观察[J].江西医药,2015,50(11):1229-1231.
[4] GEE N,XIA Q,YANG Z H,et al.Vascular endothelial injury and apoptosis in rats with severe acute pancreatitis[J].Gastroenterol Res Pract,2015,2015:235017.
[5] 赵春菱,赵晓琴.重症急性胰腺炎死亡相关因素分析及对策[J].蛇志,2012,24(4):363-365.
[6] BANKS P A,BOLLEN T L,DERVENIS C,et al.Classification of acute pancreatitis——2012:revision of the Atlanta classification and definitions by international consensus[J].Gut,2013,62(1):102-111.
[7] PIWINSKI S.Severe acute pancreatitis[J].LAMA,2004,292(11):1305.
[8] PAUL G L,MINOTI A,BANKS P A,et al.Acute pancreatitis[J].Lancet,2015,386(9988):85-96.
[9] TOMKOTER L,ERBES J,TREPTE C,et al.The efects of pancreatic microcirculatory disturbances on histopathologic tisue damage and the outcome in severe acute pancreatitis[J].Pancreas,2016,45(2):248-253.
[10] LIU L T,LI Y,FAN L Q,et al.Effect of vascular bradykinin on pancreatic microcirculation and hemorheology in rats with severeacute pancreatitis[J].Eur Rev Med Pharmacol Sci,2015,19(14):2646-2650.
[11] WARZECHA Z,SENDUR P,CERANOWICZ P,et al.Pretreatment with low doses of acenocoumarol inhibits the development of acute ischemi a/reperfusion-induced pancreatitis[J].Physiol Pharmacol,2015,66(5):731-740.
[12] 马江辰,保志军.高脂血症性急性胰腺炎的临床特征分析[J].国际消化病杂志,2019,39(1):46-49.
[13] XIAO Q W,BEI S,LE L,et al.Role of hyperlipidimia inpathogenesis of acute pancreatitis[J].Chin J Digest,2017,25(6):498-503.
[14] TOMKOTTRE L,ERBES J,TREPTE C,et al.The effects of pancreatic microcirculatory disturbances on histopathologic tissue damage and the outcome in severe acute pancreatitis[J].Pancreas,2016,45(2):248-253.
[15] TOZLU M,KAYAR Y,I.NCE A T,et al.Low molecular weight heparin treatment of acute moderate and severe pancreatitis:a randomized,controlled,open-label study[J].Turk J Gastroenterol,2019,30(1):81-87.
[16] KLEINEGRIS M C,TEN C H.Coagulation and the vessel wall in thrombosis and atherosclerosis[J].Pol Arch Med Wewn,2012,122(11):557-566.
[17] 卢义展,王湘英.微循环功能障碍在重症患者急性胰腺炎主要发病机制中的地位[J].中华胰腺病杂志,2010,10(2):144-146.
[18] LI Y,LI G,SUO L,et al.Recent advances in studies of molecular hydrogen in the treatment of pancreatitis[J].Life Sci,2021,264:118641.
[19] GARG P K,SINGH V P.Organ failure due to systemic injury in acute pancreatitis[J].Gastroenterology,2019,156(7):2008-2023.
[20] ROH J S,SOHN D H.Damage-associated molecular patterns in inflammatory diseases[J].Immune Netw,2018,18(4):18-27.
[21] HUANG Q,WU Z,CHI C,et al.Angiopoietin-2 is an early predictor for acute gastrointestinal injury and intestinal barrier dysfunction in patients with acute pancreatitis[J].Dig Dis Sci United States,2021,66(1):114-120.
[22] CHEN Y,KE L,MENG L,et al.Endothelialmarkersareassociat ed with pancreatic necrosis and overall prognosis in acute pan creatitis:a preliminary cohort study[J].Pancreatology,2017,17(1):45-50.
[23] PING C,YONGPING Z,MINMIN Q,et al.Activated protein C improves the severity of severe acute pancreatitis via up-regulating the expressions of endothelial cell protein C receptor and thrombomodulin[J].Dig Dis Sci,2010,55(6):1599-1609.
[24] MATSUMOTO T,WADA H,NOBORI T,et al.Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with disseminated intravascular coagulation[J].Clin Appl Thromb Hemost,2005,11(4):391-400.
[25] EASLER J,MUDDANA V,FURLAN A,et al.Portosplenomesenteric venous thrombosis in patients with acute pancreatitis is associated with pancreatic necrosis and usually has a benign course[J].Clin Gastroenterol Hepatol,2014,12(5):854-862.
[26] JUNARE P R,UDGIRKAR S,NAIR S,et al.Splanchnic venous thrombosis in acute pancreatitis:does anticoagulation affect outcome[J].Gastroenterology Res,2020,13(1):25-31.
[27] MENDELSON R M,ANDERSON MARSHALL M,RAMSAY D.Vascular complications of pancreatitis[J].ANZ J Surg,2005,75(12):1073-1079.
[28] REBOURS V,BOUDAOUD L,VULLIERMEU M P,et al.Extrahepatic portalvenous system thrombosis in recurrent acute and chronic alcoholic pancreatitis thrombophilia is caused by local inflammation and not thrombophilia[J].Am J Gastroenterol,2012,107(10):1579-1585.
[29] 姚辉,郭晓钟,祁兴顺,等.胰腺炎并发胰周血管异常的临床分析[J].中华胰腺病杂志,2017,17(3):158-161.
[30] GONZELEZ H J,SAHAY S J,SAAMDI B,et al.Splanchnic vein thrombosis in severe acute pancreatitis:a 2-year,single-institution experience[J].HPB (Oxford),2011,13(12):860-864.
[31] GRAY E,MULLOY B,BARROWCLIFFE T W.Heparin and low-molecular-weight heparin[J].Thromb Haemost,2008,99(5):807-818.
[32] LINDMARK E,SIEGBAHN A.Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-culture:effects of a statin,an ACE-inhibitor and a low-molecular-weight heparin[J].Thrombosis Res,2002,108(1):77-84.
[33] NING F,WANG X,SHANG L,et al.Low molecular weight heparin may prevent acute lung injury induced by sepsis in rats[J].Gene,2015,557(1):88-91.
[34] KE L,NI H B,TONG Z H,et al.Efficacy of continuous regional arterial infusion with low-molecular-weight heparin for severe acute pancreatitis in a porcine model[J].Shock,2014,41(5):443-448.
[35] QIU Q,LI G J,TANG L,et al.The efficacy of low molecular weight heparin in severe acute pancreatitis:A systematic review and meta-analysis of randomized controlled trials[J].J Dig Dis,2019,20(10):512-522.
[36] ZHOU J,ZHANG H,MAO W,et al.Efficacy and safety of early systemic anticoagulation for preventing splanchnic thrombosis in acute necrotizing pancreatitis[J].Pancreas,2020,49(9):1220-1224.
[37] DU J D,ZHENG X,HUANG Z Q,et al.Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancreatitis[J].Exp Ther Med,2014,8(1):141-146.
[38] TOZLU M,KAYAR Y,İNCE A T,et al.Low molecular weight heparin treatment of acute moderate and severe pancreatitis:a randomized,controlled,open-label study[J].Turk J Gastroenterol,2019,30(1):81-87.
[39] EGUCHI T,TSUJI Y,YAMASHITA H,et al.Efficacy of recombinant human soluble thrombomodulin in preventing walled-off necrosis in severe acute pancreatitis patients[J].Pancreatology,2015,15(5):485-490.
[40] WARZECHA Z,SENDUR P,CERANOCZ P.et al.Pretreatment with low doses of acenocoumarol inhibits the development of acute ischemia/reperfusion-induced pancreatitis[J].Physiol Pharmacol,2015,66(5):731-740.
[41] ANDERSSON E,AXELSSON J,PEDERSEN L,et al.Treatmentwithanti-factorⅦIainacute pancreatitis in rats:blocks both coagulation and inflammation[J].Scand J Gastroenterol,2007,42(6):765-700.
[42] CHEN P,ZHANG Y,QIAO M,et al.Activated protein C,an anticoagulant polypeptide,ameliorates severe acute pancreatitis via regulation of mitogen-activated protein kinases[J].Gastroenterol,2007,42(11):887-896.
[43] YAMENEL L,MAS M R,COMERT B,et al.The effect of activated protein C on experimental acute necrotizing pancreatitis[J].Crit Care,2005:9(3):184-190.
[44] CHEN C,XIA S H,CHEN H,et al.Therapy for acute pancreatitis with platelet-activating factor receptor antagonists[J].World J Gastroenterol,2008,14(30):4735-4738.
[45] KEARON C,AKLE A,COMEROTA A J,et al.Antithrombotic therapy for VTE disease:antithrombotic therapy and prevention of thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2):419-496.
[46] JANCZAK D T,MIMIER M K,MCBANE R D,et al.Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location[J].Mayo Clin Proc,2018,93(1):40-47.
[47] NAGAOKI Y,AIKATA H,DAIJYO K,et al.Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis[J].Hepatol Res,2018,48(1):51-58.
[48] WILLIAM N,GABIJA L,GEORGE R,et al.Current practice of anticoagulant in the treatment of splanchnic vein thrombosis secondary to acute pancreatitis[J].Hepatobiliary Pancreat Dis Int,2020,19(2):116-121.
[49] DANILO P,ROSSELLA C,MARIA G,et al.Anticoagulant therapy in the treatment of splanchnic vein thrombosis associated to acute pancreatitis:a 3year singlecentre experience[J].Intern Emerg Med,2020,15(6):1021-1029.